Phase II trial of imatinib mesylate in patients with metastatic melanoma
Open Access
- 19 August 2008
- journal article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 99 (5), 734-740
- https://doi.org/10.1038/sj.bjc.6604482
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Multicenter Phase II trial of high‐dose imatinib mesylate in metastatic melanomaCancer, 2006
- A Missense Mutation in KIT Kinase Domain 1 Correlates with Imatinib Resistance in Gastrointestinal Stromal TumorsCancer Research, 2004
- Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal TumorJournal of Clinical Oncology, 2003
- Apparent KIT Ser715 Deletion in GIST mRNA Is Not Detectable in Genomic DNA and Represents a Previously Known Splice Variant of KIT TranscriptThe American Journal of Pathology, 2002
- Mutations of the BRAF gene in human cancerNature, 2002
- Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine KinaseScience, 2000
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemiaJCI Insight, 2000
- Expression of platelet-derived growth factor (PDGF)-A, PDGF-B and the PDGF-alpha receptor, but not the PDGF-beta receptor, in human malignant melanoma in vivoBritish Journal of Dermatology, 1996
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989